SEC Tracker
Get the app

Alumis ALMS

Alumis (ALMS) has filed its Q3 2025 Form 10-Q, providing investors with an update on the company's financial performance and operational status. The filing highlights the company's quarterly results, including revenue, earnings, and cash flow, which are crucial indicators of the business's short-term health and trajectory. This information is essential for investors to assess Alumis's current position and make informed decisions about the company's prospects.

Form
10-Q
Filed
Importance
Notable

Open in the appGet the appView on EDGAR

Get an email when Alumis files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Crescent Biopharma CBIO public float $177M, Jun 30, 2025
  2. Editas Medicine EDIT public float $191M, Jun 30, 2025
  3. Omeros OMER public float $172M, Jun 30, 2025
  4. Palvella Therapeutics PVLA public float $197M, Jun 30, 2025
  5. Lexicon Pharmaceuticals LXRX public float $170M, Jun 30, 2025